| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbef8699192e183ec648f9b9d6e49fff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c73105d13663fe5a51da76f40a10cc08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a92445b03d3abcd046386534d7f3b88f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b65e39051ca711b5663588d6c0829f9c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e7f008abe8bea1686a86208346bbd00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcbab91ce927b2a0fd7d3771cd3b6e83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4585885092dd048c78bbf26c7fe84fa0 |
| publicationDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010132742-A1 |
| titleOfInvention |
Methods and compositions for modulating erbb2 activity |
| abstract |
Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been disovered that Erbin plays a role in the myelination of neurons of the peripheral nervouse system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108048484-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108048484-B |
| priorityDate |
2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |